Last updated on March 2019

Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)

Brief description of study

This study aims to compare treatment with imipenem/relebactam/cilastatin (IMI/REL) as a fixed-dose combination (FDC) with piperacillin/tazobactam (PIP/TAZ) FDC in participants with hospital-acquired and ventilator-associated bacterial pneumonia. The primary hypothesis is that IMI/REL is non-inferior to PIP/TAZ in the incidence rate of all-cause mortality.

Clinical Study Identifier: NCT02493764

Contact Investigators or Research Sites near you

Start Over

Call for Information (Investigational Site 0525)

Philadelphia, PA United States

MSD Brasil

Sao Paulo, Brazil

Merck Canada

Kirkland, QC Canada

MDS Colombia SAS

Bogota, Colombia

Merck Sharp & Dohme OU

Tallinn, Estonia

MSD France

Paris, France


Guatemala, Guatemala

MSD Italia S.r.l.

Rome, Italy


Chiyoda-Ku, Tokyo, Japan


Seoul, Korea, Republic of


Mexico City, Mexico

Merck Sharp & Dohme IDEA, Inc.

Moscow, Russian Federation

MSD Ukraine LLC

Kiev, Ukraine

UAB "Merck Sharp & Dohme"

Vilnius, Lithuania

MSD Norge A/S

Drammen, Norway

Merck Sharp & Dohme d.o.o

Zagreb, Croatia

Merck Sharp & Dohme

Belgrade, Serbia

Merck Sharp & Dohme Lda.

Paco D'arcos, Portugal

Merck Sharp & Dohme

North Ryde, Australia

Merck Sharp & Dohme

Buenos Aires, Argentina


Prague, Czechia

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.